NEW YORK (GenomeWeb News) – Epigenetics-based molecular diagnostics company RiboMed Biotechnologies today announced a partnership with the Austrian Institute of Technology to develop and commercialize an assay based on lung cancer DNA methylation biomarkers discovered and validated by researchers at the institute.

The biomarkers allow for the early detection of lung cancer, as well as the subtyping of non-small cell lung cancer into adenocarcinoma or squamous cell carcinoma, which are treated with different therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: Leukemia-like disease in soft-shell clams, mNET-seq method for profiling growing transcripts, and more.

While James Watson and Francis Crick are credited for discovering the structure of DNA, Rich proved their theory of a double helix structure was correct when he produced a distinct image of the structure.

Nature News reports that early users of Oxford Nanopore's hand-held MinIon are giddy about the technology and its uses. 

According to MIT Technology Review, Apple is collaborating with researchers to develop apps for consumer DNA testing.